Skip to main content
. 2021 Jun 1;59(5):602–607. doi: 10.1016/j.resinv.2021.05.002

Table 1.

Demographic and clinical characteristics of the study population.

Parameter Population (n = 96)
Age
M ± SD 69.65 ± 14.33
median (IQR 25–75) 66.00 (57.00–88.00)
Female Sex (%) 28.9
BMI
M ± SD 27.98 ± 5.00
median (IQR) 27.68 (23.89–31.25)
Smoking habit (%)
 Never smokers 36.1
 Ex-smokers 42.3
 Current smokers 3.1
CCI
M ± SD 4.25 ± 2.66
median (IQR) 4.00 (2.00–6.00)
Asthma (%) 17.5
COPD (%) 17.5
Hypertension (%) 70.1
Renal Failure (%) 44.3
Congestive heart failure (%) 22.7
Chronic ischemic heart failure (%) 27.8
Neurological comorbidities (%) 17.6
Number of peripheral lymphocyte cells
M ± SD 928.39 ± 637.35
median (IQR) 783.24 (629.18–1039.88)
LDH
M ± SD 332.20 ± 113.31
median (IQR) 342.00 (245.00–396.00)
CRP
M ± SD 116.74 ± 79.99
median (IQR) 106.00 (69.30–167.00)
D-dimer
M ± SD 2448.33 ± 3811.22
median (IQR) 947.00 (581.00–2280.00)
PaO2/FiO2 ratio at admission
M ± SD 209.58 ± 94.00
median (IQR) 198.00 (123.00–273.00)
Respiratory support at admission (%)
Low flow oxygen 9.3
HNFC 3.1
CPAP 38.1
BPAP 36.1
IMV through tracheostomy 7.2
Treatment
 enoxaparin (%) 81%
 azithromycin (%) 80%
 lopinavir/ritonavir (%) 38%
 hydroxychloroquine (%) 74%
 tocilizumab (%) 6%
 corticosteroids (%) 25%
Total Days of Hospitalization in RICU
M ± SD 10.68 ± 8.94
median (IQR) 10,00 (4,00–19.00)
Exitus (%) 46.4

M, mean; SD, standard deviation; IQR, interquartile range; BMI, body mass index; CCI, Charlson comorbidity index; COPD, Chronic obstructive pulmonary disease; LDH, Lactate dehydrogenase; CRP, C-reactive protein; PaO2/FiO2 ratio, arterial oxygen partial pressure to fractional inspired oxygen; HFNC, high-flow nasal cannula; CPAP, continuous positive airway pressure; BPAP, bilevel positive airway pressure; IMV, invasive mechanical ventilation; RICU, Respiratory Intermediate Care Units.